Jacques Pepin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10427548/publications.pdf

Version: 2024-02-01

45 papers 10,857 citations

28 h-index 254184 43 g-index

46 all docs 46 docs citations

46 times ranked

7512 citing authors

#	Article	IF	CITATIONS
1	Effectiveness of fosfomycin tromethamine prophylaxis in preventing infection following transrectal ultrasound-guided prostate needle biopsy: Results from a large Canadian cohort. Journal of Global Antimicrobial Resistance, 2019, 17, 112-116.	2.2	14
2	Multilocus Variable-Number Tandem-Repeat Analysis of Clostridioides difficile Clusters in Ribotype 027 Isolates and Lack of Association with Clinical Outcomes. Journal of Clinical Microbiology, 2019, 57, .	3.9	3
3	External validation of clinical prediction rules for complications and mortality following Clostridioides difficile infection. PLoS ONE, 2019, 14, e0226672.	2.5	9
4	External validation of predictive scores for mortality following Clostridium difficile infection. Open Forum Infectious Diseases, 2017, 4, S401-S401.	0.9	0
5	External validation of clinical scores to predict complications of Clostridium difficile infection. Open Forum Infectious Diseases, 2017, 4, S402-S402.	0.9	3
6	Derivation and Validation of a Clinical Prediction Rule for Complications of Clostridium difficile Infection Using a Multicenter Prospective Cohort. Open Forum Infectious Diseases, 2017, 4, S401-S402.	0.9	0
7	Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections. American Journal of Gastroenterology, 2016, 111, 1834-1840.	0.4	74
8	Epidemic History and latrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa. Journal of Infectious Diseases, 2016, 214, 353-360.	4.0	19
9	Clinical and Healthcare Burden of Multiple Recurrences of <i>Clostridium difficile </i> Infection. Clinical Infectious Diseases, 2016, 62, 574-580.	5.8	116
10	Factors Associated With Complications of <i>Clostridium difficile </i> Prospective Cohort. Clinical Infectious Diseases, 2015, 61, 1781-1788.	5.8	46
11	The early spread and epidemic ignition of HIV-1 in human populations. Science, 2014, 346, 56-61.	12.6	515
12	Risk Factors for Recurrence, Complications and Mortality in Clostridium difficile Infection: A Systematic Review. PLoS ONE, 2014, 9, e98400.	2.5	265
13	The expansion of HIV-1 in colonial Léopoldville, 1950s: driven by STDs or STD control?. Sexually Transmitted Infections, 2012, 88, 307-312.	1.9	15
14	Periodical Antibiotic Treatment for the Control of Gonococcal and Chlamydial Infections Among Sex Workers in Benin and Ghana. Sexually Transmitted Diseases, 2012, 39, 253-259.	1.7	13
15	Increasing Risk of Infectious Complications After Transrectal Ultrasound–Guided Prostate Biopsies: Time to Reassess Antimicrobial Prophylaxis?. European Urology, 2012, 62, 453-459.	1.9	240
16	Risk of secondary cases of Clostridium difficile infection among household contacts of index cases. Journal of Infection, 2012, 64, 387-390.	3.3	28
17	Prediction Tools for Unfavourable Outcomes in Clostridium difficile Infection: A Systematic Review. PLoS ONE, 2012, 7, e30258.	2.5	73
18	Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infectious Diseases, 2010, 10, 363.	2.9	109

#	Article	IF	CITATIONS
19	GuÃas de práctica clÃnica para la infección porClostridium difficileen adultos: actualización 2010 realizada por la Sociedad de Salud Epidemiológica de Norteamérica (SHEA) y la Sociedad de Enfermedades Infecciosas de Norteamérica (IDSA). Infection Control and Hospital Epidemiology, 2010, 31, T1-T28.	1.8	6
20	Clostridium difficile Infection in the Intensive Care Unit. Journal of Intensive Care Medicine, 2010, 25, 23-30.	2.8	22
21	Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology, 2010, 31, 431-455.	1.8	2,716
22	Emergence of and Risk Factors for Ciprofloxacin-Gentamicin-Resistant <i>Escherichia coli</i> Urinary Tract Infections in a Region of Quebec. Canadian Journal of Infectious Diseases and Medical Microbiology, 2009, 20, e163-e168.	1.9	9
23	Prediction of Complicated <i>Clostridium difficile </i> Infection by Pleural Effusion and Increased Wall Thickness on Computed Tomography. Clinical Infectious Diseases, 2009, 49, 554-560.	5.8	31
24	A Tale of Two Countries: HIV Among Core Groups in Togo. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 216-223.	2.1	23
25	Risk Factors for Mortality Following Emergency Colectomy for Fulminant Clostridium difficile Infection. Diseases of the Colon and Rectum, 2009, 52, 400-405.	1.3	72
26	Comparison of Seven Techniques for Typing International Epidemic Strains of <i>Clostridium difficile</i> : Restriction Endonuclease Analysis, Pulsed-Field Gel Electrophoresis, PCR-Ribotyping, Multilocus Sequence Typing, Multilocus Variable-Number Tandem-Repeat Analysis, Amplified Fragment Length Polymorphis, and Surface Layer Protein A Gene Sequence Typing. Journal of Clinical	3.9	298
27	Microbiology, 2008, 46, 431-437. Clostridium difficile Infections in a Canadian Tertiary Care Hospital before and during a Regional Epidemic Associated with the BI/NAP1/027 Strain. Antimicrobial Agents and Chemotherapy, 2008, 52, 3180-3187.	3.2	131
28	Risk of <i>Clostridium difficile</i> Infection after Perioperative Antibacterial Prophylaxis before and during an Outbreak of Infection due to a Hypervirulent Strain. Clinical Infectious Diseases, 2008, 46, 1838-1843.	5.8	153
29	Vancomycin for the Treatment of <i>Clostridium difficile </i> li>Infection: For Whom Is This Expensive Bullet Really Magic?. Clinical Infectious Diseases, 2008, 46, 1493-1498.	5.8	70
30	Outcomes of Clostridium difficile-Associated Disease Treated With Metronidazole or Vancomycin Before and After the Emergence of NAP1/027. American Journal of Gastroenterology, 2007, 102, 2781-2788.	0.4	161
31	Impact of a Reduction in the Use of High-Risk Antibiotics on the Course of an Epidemic of Clostridium difficile-Associated Disease Caused by the Hypervirulent NAP1/027 Strain. Clinical Infectious Diseases, 2007, 45, S112-S121.	5.8	294
32	Impact of Emergency Colectomy on Survival of Patients With Fulminant Clostridium difficile Colitis During an Epidemic Caused by a Hypervirulent Strain. Annals of Surgery, 2007, 245, 267-272.	4.2	316
33	Fluoroquinolones and Risk for Methicillin-Resistant <i>Staphylococcus aureus</i> , Canada. Emerging Infectious Diseases, 2006, 12, 1398-1405.	4.3	58
34	Improving Second-Generation Surveillance. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 490-493.	2.1	10
35	Management and Outcomes of a First Recurrence of Clostridium difficile-Associated Disease in Quebec, Canada. Clinical Infectious Diseases, 2006, 42, 758-764.	5.8	223
36	Editorial Commentary:Improving the Treatment ofClostridium difficile–Associated Disease: Where Should We Start?. Clinical Infectious Diseases, 2006, 43, 553-555.	5.8	20

#	Article	IF	CITATIONS
37	Emergence of Fluoroquinolones as the Predominant Risk Factor for Clostridium difficile-Associated Diarrhea: A Cohort Study during an Epidemic in Quebec. Clinical Infectious Diseases, 2005, 41, 1254-1260.	5.8	898
38	Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. Cmaj, 2005, 173, 1037-1042.	2.0	536
39	Increasing Risk of Relapse after Treatment of Clostridium difficile Colitis in Quebec, Canada. Clinical Infectious Diseases, 2005, 40, 1591-1597.	5.8	515
40	Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet, The, 2005, 366, 1079-1084.	13.7	1,321
41	Transactional sex is the driving force in the dynamics of HIV in Accra, Ghana. Aids, 2004, 18, 917-925.	2.2	148
42	Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Cmaj, 2004, 171, 466-472.	2.0	988
43	A Randomized Placebo-Controlled Trial of the Impact of Multiple Micronutrient Supplementation on HIV-1 Genital Shedding Among Thai Subjects. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1216-1218.	2.1	4
44	A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV-infected individuals living in Bangkok. Aids, 2003, 17, 2461-2469.	2.2	137
45	HIV Infection Among Sex Workers in Accra: Need to Target New Recruits Entering the Trade. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 358-366.	2.1	37